vadastuximab talirine (SGN-CD33A)

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

DNA replication inhibitor, CD33-targeted antibody-drug conjugate

Related drugs:

‹

›

CD33 expression	Acute Myelogenous Leukemia	CD33 expression	Acute Myelogenous Leukemia	SGN-CD33A Sensitive: C3 – Early Trials SGN-CD33A Sensitive : C3	SGN-CD33A Sensitive: C3 – Early Trials SGN-CD33A Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	SGN-CD33A Sensitive: D – Preclinical SGN-CD33A Sensitive : D	SGN-CD33A Sensitive: D – Preclinical SGN-CD33A Sensitive : D

Associations
(2)